Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IMMP

Immutep (IMMP)

Immutep Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMMP
DateTimeSourceHeadlineSymbolCompany
03/05/20248:00AMGlobeNewswire Inc.Immutep Announces First Clinical Data from 90mg Dosing of EftiNASDAQ:IMMPImmutep Ltd
01/30/20244:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
01/30/20248:00AMGlobeNewswire Inc.Immutep Quarterly Activities Report Q2 FY24NASDAQ:IMMPImmutep Ltd
01/04/20248:00AMGlobeNewswire Inc.First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial CancerNASDAQ:IMMPImmutep Ltd
12/21/20238:00AMGlobeNewswire Inc.Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
12/21/20236:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
12/07/20238:00AMGlobeNewswire Inc.Immutep Receives A$2.6 million R&D Tax Incentive from French GovernmentNASDAQ:IMMPImmutep Ltd
11/22/20238:00AMGlobeNewswire Inc.Immutep Announces Site Expansion for INSIGHT-003 Phase I TrialNASDAQ:IMMPImmutep Ltd
11/09/20238:00AMGlobeNewswire Inc.Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaNASDAQ:IMMPImmutep Ltd
11/06/20238:00AMGlobeNewswire Inc.Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
11/03/202312:00PMGlobeNewswire Inc.Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
11/03/20236:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
11/02/20238:00AMGlobeNewswire Inc.Immutep to Participate in November Investor EventsNASDAQ:IMMPImmutep Ltd
10/31/20238:00AMGlobeNewswire Inc.Immutep Quarterly Activities Report Q1 FY24NASDAQ:IMMPImmutep Ltd
10/25/20238:00AMGlobeNewswire Inc.Immutep receives ~A$1.13 million R&D Tax IncentiveNASDAQ:IMMPImmutep Ltd
10/25/20236:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
10/24/20238:00AMGlobeNewswire Inc.Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
10/24/20236:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
10/23/20238:00AMGlobeNewswire Inc.Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
10/16/20238:00AMGlobeNewswire Inc.Immutep Announces Publication of Abstracts at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
10/03/20238:00AMGlobeNewswire Inc.Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:IMMPImmutep Ltd
09/21/20238:00AMGlobeNewswire Inc.Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseNASDAQ:IMMPImmutep Ltd
09/05/20239:00AMGlobeNewswire Inc.Immutep to Participate in September Investor ConferencesNASDAQ:IMMPImmutep Ltd
08/01/20238:00AMGlobeNewswire Inc.Immutep Receives Positive Scientific Advice from European Medicines AgencyNASDAQ:IMMPImmutep Ltd
07/31/20238:00AMGlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY23NASDAQ:IMMPImmutep Ltd
07/31/20238:00AMGlobeNewswire Inc.Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
07/28/20238:00AMGlobeNewswire Inc.First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
07/28/20236:31AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
06/28/20236:02AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
06/27/20238:00AMGlobeNewswire Inc.Immutep Completes A$80 Million Capital RaiseNASDAQ:IMMPImmutep Ltd
 Showing the most relevant articles for your search:NASDAQ:IMMP